Joel S. Marcus, JD, CPA , is the full-time Executive Chairman and Founder of Alexandria, a real estate investment trust (REIT) that pioneered life science real estate and transformed it from a specialty niche to a mainstream asset class. Alexandria is the preeminent, largest, and longest-tenured owner, operator, and developer uniquely focused on collaborative Megacampus ecosystems in AAA life science innovation cluster locations. Prior to April 2018, Mr. Marcus served as the company s Chairman, Chief Executive Officer, and President. Since co-founding the company in 1994 as a garage startup with $19 million in Series A capital, Mr. Marcus has led the remarkable growth of Alexandria into an S&P 500 company and the leading REIT focused on the life science industry, with a total market capitalization of $20.75 billion and an operating asset base in North America of 35.9 million RSF as of December 31, 2025 . Alexandria was named the NAIOP 2019 Developer of the Year and has earned seven Gold and eight overall Nareit Investor CARE (Communications and Reporting Excellence) Awards in recognition of superior investor communications among REITs. The company has been named by Newsweek as one of America s Most Charitable Companies in 2026, one of the Most Trustworthy Companies in America for four consecutive years from 2023 to 2026, and one the World s Most Trustworthy Companies in 2024 and 2025, reinforcing Alexandria s standing as the most trusted brand in life science real estate. In addition, Mr. Marcus received the inaugural Bisnow Life Sciences Icon & Influencer Award in September 2024. This prestigious award highlights Mr. Marcus and Alexandria s significant long-term contributions to and lasting impact on the life science real estate sector and broader life science industry. He was also named one of Real Estate Forum s 2017 Best Bosses in commercial real estate and was previously a recipient of the EY Entrepreneur Of The Year Award (Los Angeles Real Estate). Mr. Marcus has led the Company s efforts to build the largest and most creditworthy tenant base in the life science real estate industry by cultivating a highly diversified roster of leading, investment- grade and publicly-traded large-cap organizations. These tenants recognize the advantages of Alexandria s specialized, mission-critical infrastructure in supporting their advanced scientific research. Alexandria s sector-leading tenant roster includes many of the world s most sophisticated and well- capitalized biopharmaceutical and life science innovators, including Eli Lilly, Novartis, Bristol Myers Squibb, Sanofi, AstraZeneca, and Merck, each of whom entrusts Alexandria with the long-term occupancy of their most essential R&D facilities. In 2025, under Mr. Marcus s leadership, the Company secured long-term leases with a weighted-average lease term of approximately 12 years, including the largest life science lease in Company history: a 16-year build-to-suit lease expansion aggregating 466,598 RSF for Novartis, a long-standing multinational pharmaceutical tenant, at the Campus Point by Alexandria Megacampus in our University Town Center submarket. Taken together, Alexandria s premier tenant composition and long-duration leasing activity continue to translate directly into durable, high quality cash flows. As of December 31, 2025 , investment-grade or publicly-traded large-cap tenants accounted for 84% of annual rental revenue from Alexandria s top 20 tenants and 53% of total annual rental revenue. The Company has maintained strong rent collections, even through periods of macroeconomic volatility, demonstrating the stability and resilience of these relationships. The strength of Alexandria s tenants is further reflected in their scientific achievements: nearly half of all FDA approved therapies over the past decade were developed by companies located within Alexandria s campuses, underscoring not only the financial strength of Alexandria s tenants but also their profound impact on global biomedical innovation. Collectively, these accomplishments highlight how Mr. Marcus s vision and disciplined execution have positioned Alexandria as the landlord of choice for the most influential and mission-driven innovators in life sciences. His leadership has built not only the largest, but also the most creditworthy and mission-critical tenant base in the life science real estate industry, reinforcing Alexandria s standing as the premier life science real-estate platform and the anchor infrastructure provider to the world s leading R&D institutions. During Mr. Marcus s more than three decades leading Alexandria, he has built a best-in-class company with a differentiated business model and a unique mission to create and grow life science ecosystems and clusters to advance human health that continue to distinguish Alexandria from all other REITs. Guided by Alexandria s important mission, Mr. Marcus established four strategic and integrated verticals encompassing real estate, venture investments, thought leadership, and corporate responsibility that together catalyze life-changing innovation and drive positive change for the benefit of human health and society. Mr. Marcus has proven management and leadership skills. In recognition of the company s outstanding track record across all aspects of its one-of-a-kind, mission-driven business, renowned author and business strategist Jim Collins has said, Alexandria has achieved the three outputs that define a great company: Superior Long-Term Results, Distinctive Impact, and Lasting Endurance. Mr. Marcus accelerated Alexandria s extraordinary growth through the tremendous execution of its visionary ecosystem-building and cluster development strategy in key locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. He also founded and continues to lead Alexandria Venture Investments, the company s strategic venture capital platform. Since the platform s inception in 1996, it has actively invested in disruptive life science companies that are advancing transformative new modalities, platforms, and innovative medicines to meaningfully improve human health. Mr. Marcus introduced the company s thought leadership vertical in 2011, when he co-founded the renowned Alexandria Summit . Established to serve as a highly collaborative, neutral platform, the Alexandria Summit convenes a world-class network of visionary stakeholders to explore the most important issues facing human health and leverage its powerful collective voice to foster impactful collaborations and shape policy. Mr. Marcus leads Alexandria s pioneering corporate responsibility initiatives, which aim to develop and implement scalable, long-term solutions to some of the nation s most urgent challenges, including disease and other threats to human health, hunger and food insecurity, deficiencies in support services for the military and their families, education disparities, and the mental health crisis. He has been deeply engaged with several highly impactful local and national non-profit organizations for many years, including through his service on the board of directors of the Emily Krzyzewski Center, National Medal of Honor Museum, Navy SEAL Foundation, and TOPGUN Association. Prior to co-founding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions. During that time, he acquired expertise in the biopharmaceutical industry and was one of the principal architects of Kirin- Amgen, Inc., the trailblazing biotechnology joint venture established in 1984. He was also a practicing certified public accountant and tax manager with Arthur Young & Co., where he focused on the financing and taxation of REITs. Mr. Marcus served on the board of directors of Intra-Cellular Therapies, Inc. from 2006 until its acquisition by Johnson & Johnson in 2025. Mr. Marcus received his undergraduate and Juris Doctor degrees from the University of California, Los Angeles.